Trivium Point Advisory’s Cardlytics CDLX Stock Holding History

Trivium Point Advisory’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-312	Closed	-$259K	–	252
2021 Q3	$259K	Hold	312	–	–	0.06%	197
2021 Q2	$395K	Buy	+312	New	+$352K	0.1%	165
2021 Q1	–	Sell	-169	Closed	-$244K	–	199
2020 Q4	$244K	Buy	+169	New	+$180K	0.07%	171

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Trivium Point Advisory's CDLX Position: Q4 2021 in Review

Trivium Point Advisory sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 312 shares — an estimated $259K sold.

Trivium Point Advisory first reported a position in CDLX in Q4 2020 and held it in 3 quarters. The position peaked at $395K in Q2 2021. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

Trivium Point Advisory reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
Trivium Point Advisory sold 312 Cardlytics shares in Q4 2021, an estimated $259K.
Trivium Point Advisory first reported a position in Cardlytics in Q4 2020 and held it in 3 quarters.
Trivium Point Advisory's Cardlytics position peaked at $395K in Q2 2021.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on Trivium Point Advisory's 13F filing for Q4 2021, filed 10 Feb 2022.